000005513 001__ 5513
000005513 005__ 20180208194813.0
000005513 0247_ $$2pmid$$apmid:19345722
000005513 0247_ $$2DOI$$a10.1016/j.neuroscience.2009.03.068
000005513 0247_ $$2WOS$$aWOS:000269404600044
000005513 037__ $$aPreJuSER-5513
000005513 041__ $$aeng
000005513 082__ $$a610
000005513 084__ $$2WoS$$aNeurosciences
000005513 1001_ $$0P:(DE-Juel1)VDB71164$$aCremer, C.M.$$b0$$uFZJ
000005513 245__ $$aPentylenetetrazole-induced seizures affect binding site densities for GABA, glutamate and adenosine receptors in the rat brain
000005513 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2009
000005513 300__ $$a490 - 499
000005513 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000005513 3367_ $$2DataCite$$aOutput Types/Journal article
000005513 3367_ $$00$$2EndNote$$aJournal Article
000005513 3367_ $$2BibTeX$$aARTICLE
000005513 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000005513 3367_ $$2DRIVER$$aarticle
000005513 440_0 $$04579$$aNeuroscience$$v163$$x0306-4522$$y1
000005513 500__ $$aRecord converted from VDB: 12.11.2012
000005513 520__ $$aPentylenetetrazole (PTZ) is a convulsant used to model epileptic seizures in rats. In the PTZ-model, altered heat shock protein 27 (HSP-27) expression highlights seizure-affected astrocytes, which play an important role in glutamate and GABA metabolism. This raises the question whether impaired neurotransmitter metabolism leads to an imbalance in neurotransmitter receptor expression. Consequently, we investigated the effects of seizures on the densities of seven different neurotransmitter receptors in rats which were repeatedly treated with PTZ (40 mg/kg) over a period of 14 days. Quantitative in vitro receptor autoradiography was used to measure the regional binding site densities of the glutamate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA) receptors, the adenosine receptor type 1 (A(1)), which is part of the system controlling glutamate release, and the gamma-aminobutyric acid (GABA) receptors GABA(A) and GABA(B) as well as the GABA(A)-associated benzodiazepine (BZ) binding sites in each rat. Our results demonstrate altered receptor densities in brain regions of PTZ-treated animals, including the HSP-27 expressing foci (i.e. amygdala, piriform and entorhinal cortex, dentate gyrus). A general decrease of kainate receptor densities was observed together with an increase of NMDA binding sites in the hippocampus, the somatosensory, piriform and the entorhinal cortices. Furthermore, A(1) binding sites were decreased in the amygdala and hippocampal CA1 region (CA1), while BZ binding sites were increased in the dentate gyrus and CA1. Our data demonstrate the impact of PTZ induced seizures on the densities of kainate, NMDA, A(1) and BZ binding sites in epileptic brain. These changes are not restricted to regions showing glial impairment. Thus, an altered balance between different excitatory (NMDA) and modulatory receptors (A(1), BZ binding sites, kainate) shows a much wider regional distribution than that of glial HSP-27 expression, indicating that receptor changes are not following the glial stress responses, but may precede the HSP-27 expression.
000005513 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000005513 588__ $$aDataset connected to Web of Science, Pubmed
000005513 650_2 $$2MeSH$$aAnimals
000005513 650_2 $$2MeSH$$aBinding Sites: drug effects
000005513 650_2 $$2MeSH$$aBinding Sites: physiology
000005513 650_2 $$2MeSH$$aBinding, Competitive: drug effects
000005513 650_2 $$2MeSH$$aBinding, Competitive: physiology
000005513 650_2 $$2MeSH$$aBrain: anatomy & histology
000005513 650_2 $$2MeSH$$aBrain: metabolism
000005513 650_2 $$2MeSH$$aBrain: physiopathology
000005513 650_2 $$2MeSH$$aConvulsants: pharmacology
000005513 650_2 $$2MeSH$$aDisease Models, Animal
000005513 650_2 $$2MeSH$$aEpilepsy: chemically induced
000005513 650_2 $$2MeSH$$aEpilepsy: metabolism
000005513 650_2 $$2MeSH$$aEpilepsy: physiopathology
000005513 650_2 $$2MeSH$$aHSP27 Heat-Shock Proteins: drug effects
000005513 650_2 $$2MeSH$$aHSP27 Heat-Shock Proteins: metabolism
000005513 650_2 $$2MeSH$$aMale
000005513 650_2 $$2MeSH$$aNeuroglia: metabolism
000005513 650_2 $$2MeSH$$aPentylenetetrazole: pharmacology
000005513 650_2 $$2MeSH$$aRats
000005513 650_2 $$2MeSH$$aRats, Wistar
000005513 650_2 $$2MeSH$$aReceptor, Adenosine A1: drug effects
000005513 650_2 $$2MeSH$$aReceptor, Adenosine A1: metabolism
000005513 650_2 $$2MeSH$$aReceptors, AMPA: drug effects
000005513 650_2 $$2MeSH$$aReceptors, AMPA: metabolism
000005513 650_2 $$2MeSH$$aReceptors, GABA: metabolism
000005513 650_2 $$2MeSH$$aReceptors, GABA-A: drug effects
000005513 650_2 $$2MeSH$$aReceptors, GABA-A: metabolism
000005513 650_2 $$2MeSH$$aReceptors, GABA-B: drug effects
000005513 650_2 $$2MeSH$$aReceptors, GABA-B: metabolism
000005513 650_2 $$2MeSH$$aReceptors, Glutamate: metabolism
000005513 650_2 $$2MeSH$$aReceptors, Kainic Acid: drug effects
000005513 650_2 $$2MeSH$$aReceptors, Kainic Acid: metabolism
000005513 650_2 $$2MeSH$$aReceptors, N-Methyl-D-Aspartate: drug effects
000005513 650_2 $$2MeSH$$aReceptors, N-Methyl-D-Aspartate: metabolism
000005513 650_2 $$2MeSH$$aReceptors, Purinergic P1: metabolism
000005513 650_2 $$2MeSH$$aStress, Physiological: physiology
000005513 650_2 $$2MeSH$$aSynaptic Transmission: drug effects
000005513 650_2 $$2MeSH$$aSynaptic Transmission: physiology
000005513 650_7 $$00$$2NLM Chemicals$$aConvulsants
000005513 650_7 $$00$$2NLM Chemicals$$aHSP27 Heat-Shock Proteins
000005513 650_7 $$00$$2NLM Chemicals$$aHspb1 protein, rat
000005513 650_7 $$00$$2NLM Chemicals$$aReceptor, Adenosine A1
000005513 650_7 $$00$$2NLM Chemicals$$aReceptors, AMPA
000005513 650_7 $$00$$2NLM Chemicals$$aReceptors, GABA
000005513 650_7 $$00$$2NLM Chemicals$$aReceptors, GABA-A
000005513 650_7 $$00$$2NLM Chemicals$$aReceptors, GABA-B
000005513 650_7 $$00$$2NLM Chemicals$$aReceptors, Glutamate
000005513 650_7 $$00$$2NLM Chemicals$$aReceptors, Kainic Acid
000005513 650_7 $$00$$2NLM Chemicals$$aReceptors, N-Methyl-D-Aspartate
000005513 650_7 $$00$$2NLM Chemicals$$aReceptors, Purinergic P1
000005513 650_7 $$054-95-5$$2NLM Chemicals$$aPentylenetetrazole
000005513 650_7 $$2WoSType$$aJ
000005513 65320 $$2Author$$aepilepsy
000005513 65320 $$2Author$$aanimal model
000005513 65320 $$2Author$$aneurotransmitter receptors
000005513 65320 $$2Author$$aPTZ
000005513 7001_ $$0P:(DE-Juel1)VDB1208$$aPalomero-Gallagher, N.$$b1$$uFZJ
000005513 7001_ $$0P:(DE-HGF)0$$aBidmon, H.-J.$$b2
000005513 7001_ $$0P:(DE-HGF)0$$aSchleicher, A.$$b3
000005513 7001_ $$0P:(DE-HGF)0$$aSpeckmann, E.-J.$$b4
000005513 7001_ $$0P:(DE-Juel1)131714$$aZilles, K.$$b5$$uFZJ
000005513 773__ $$0PERI:(DE-600)1498423-4$$a10.1016/j.neuroscience.2009.03.068$$gVol. 163, p. 490 - 499$$p490 - 499$$q163<490 - 499$$tNeuroscience$$v163$$x0306-4522$$y2009
000005513 8567_ $$uhttp://dx.doi.org/10.1016/j.neuroscience.2009.03.068
000005513 909CO $$ooai:juser.fz-juelich.de:5513$$pVDB
000005513 9131_ $$0G:(DE-Juel1)FUEK409$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000005513 9141_ $$y2009
000005513 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000005513 9201_ $$0I:(DE-Juel1)INM-2-20090406$$gINM$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000005513 9201_ $$0I:(DE-82)080010_20140620$$gJARA$$kJARA-BRAIN$$lJülich-Aachen Research Alliance - Translational Brain Medicine$$x1
000005513 970__ $$aVDB:(DE-Juel1)113128
000005513 980__ $$aVDB
000005513 980__ $$aConvertedRecord
000005513 980__ $$ajournal
000005513 980__ $$aI:(DE-Juel1)INM-2-20090406
000005513 980__ $$aI:(DE-82)080010_20140620
000005513 980__ $$aUNRESTRICTED
000005513 981__ $$aI:(DE-Juel1)VDB1046